treatment
Transplants for MDS and Severe Aplastic Anemia - 2023 Omaha Patient and Family Hybrid Conference
Managing PNH and Complications from the Omaha Patient & Family Hybrid Conference 2023
PNH Non-Transplant Therapies and Management -2023 Omaha Patient -Family Hybrid Conference
From the 2023 Omaha Patient and Family Hybrid Conference: PNH Non-Transplant Therapies with Dr. Alex Nester. Learn symptom management and options for therapies in this session which includes questions from the audience.
Low-Risk MDS (Myelodysplastic Syndromes) Omaha Patient and Family Hybrid Conference 2023
Dr. Vijaya Bhatt discusses Low-Risk MDS in accessible terminology during this session from the 2023 Omaha, NE, Patient and Family Hybrid Conference.
Afaf Osman, MD
Osman, Afaf
Hematologist/Oncologist
Huntsman Cancer Center, University of Utah
Online Profile:
Sagar S. Patel, MD
Patel, Sagar
Assistant Professor, Huntsman Cancer Institute
Huntsman Cancer Institute
Dr. Patel’s clinical and research expertise is in Blood and Marrow Transplantation (BMT). He has a particular interest in allogeneic hematopoietic cell transplantation as well as cellular therapies such as CAR-Ts for the treatment of malignant and benign hematologic diseases in adult patients. Dr. Patel’s research interests focus on the management of potential complications of such therapy including disease relapse and graft-versus-host disease. His work includes research and committee collaborations through such national and international organizations as ASTCT, CIBMTR, ASH, and EBMT.
Online Profile:
Alex Nester, MD
Nester, Alex
Assistant Professor, Division of Oncology & Hematology
University of Nebraska Medical Center
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials Omaha Patient and Family Hybrid Conference 2023
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials with Dr. Prajwal Dhakal